University of Alabama: Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation
June 20, 2023
June 20, 2023
BIRMINGHAM, Alabama, June 20 (TNSjou) -- The University of Alabama issued the following news:
Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.
These improvements -- as measured by a significantly lower annualized rate of acute exacerbations, si . . .
Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine.
These improvements -- as measured by a significantly lower annualized rate of acute exacerbations, si . . .